Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas

77Citations
Citations of this article
130Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Local recurrence of glioblastomas is a major cause of patient mortality after definitive treatment. This review discusses the roles of the chemokine stromal cell-derived factor-1 and its receptor CXC chemokine receptor 4 (CXCR4) in affecting the sensitivity of glioblastomas to irradiation. Blocking these molecules prevents or delays tumour recurrence after irradiation by inhibiting the recruitment of CD11b monocytes/macrophages that participate in revascularising the tumour. We review the literature pertaining to the mechanism by which revascularisation occurs following tumour irradiation using experimental models. Areas of interest and debate in the literature include the process by which endothelial cells die after irradiation and the identity/origin of the cells that reconstitute the tumour blood vessels after injury. Understanding the processes that mediate tumour revascularisation will guide the improvement of clinical strategies for preventing recurrence of glioblastoma after irradiation. © 2011 Cancer Research UK All rights reserved.

Cite

CITATION STYLE

APA

Tseng, D., Vasquez-Medrano, D. A., & Brown, J. M. (2011, June 7). Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. British Journal of Cancer. https://doi.org/10.1038/bjc.2011.169

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free